This article is more than 5 years old. Information may no longer be current.

ARTEMIS

Issue: March 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Assessment of P2Y12 inhibitor persistence and potential reductions in the risk for major adverse CV events in patients with MI when co-payment barriers were removed for P2Y12 inhibitors.